Disease extent according to baseline [18F]fluorodeoxyglucose PET/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer.
Florien J G van AmstelCornelis M de MooijJanine M SimonsCristina MiteaPaul J van DiestPatty J NelemansCarmen C van der PolErnest J T LuitenLinetta B KoppertMarjolein L SmidtThiemo J A van Nijnattennull nullPublished in: The British journal of surgery (2024)
Molecular subtype is a significant predictor of axillary pCR after neoadjuvant systemic therapy, whereas axillary disease extent according to baseline [18F]fluorodeoxyglucose PET/CT is not.